{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:10:25Z","timestamp":1756285825942,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>We report three patients with ophthalmic herpes zoster (HZ) manifestations on the background diagnosis of multiple myeloma (MM). It seems that immunocompromised status has caused reactivation of the varicella zoster virus (VZV) producing a well-characterised neurological syndrome and subsequent postherpetic neuralgia in two patients. One patient experienced lymphocytic leptomeningitis resulting in unilateral optic neuritis. All patients received similar myeloma disease-specific treatment prior to HZ reactivation. All patients were treated with thalidomide and steroids, and they thereafter underwent autologous stem cell transplantation. Prior to HZ reactivation they received new immunomodulatory drugs in the form of thalidomide in addition to bortezomib (2 patients) and lenalidomide (1 patient). Immediate specific antiviral therapy was successfully applied with intravenous acyclovir for 10\u2005days, followed by long-term oral famciclovir maintenance. Two patients progressed to have chronic HZ ophthalmicus and postherpetic neuralgia requiring ongoing antiviral therapy and neuroepileptic medications for the neuropathic pain.<\/jats:p>","DOI":"10.1136\/bcr-2012-007625","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T02:08:12Z","timestamp":1361412492000},"page":"bcr2012007625","source":"Crossref","is-referenced-by-count":5,"title":["Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation"],"prefix":"10.1136","volume":"2013","author":[{"given":"Alhossain A","family":"Khalafallah","sequence":"first","affiliation":[{"name":"Department of Haematology, Launceston General Hospital, Launceston, Tasmania, Australia"},{"name":"Department of Medicine, Launceston General Hospital, Launceston, Tasmania, Australia"},{"name":"School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Woodgate","sequence":"additional","affiliation":[{"name":"Department of Medicine, Launceston General Hospital, Launceston, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurien","family":"Koshy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Launceston General Hospital, Launceston, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Patrick","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Eye Hospital, Launceston, Tasmania, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,2,20]]},"reference":[{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.15"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.4","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"29","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.5","first-page":"237.40","article-title":"Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma","volume":"8","author":"Kim","year":"2008","journal-title":"Clin Lymphoma Leukaemia Myeloma"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.V108.11.3535.3535","article-title":"Analysis of varicella zoster virus reactivation among bortezomib-treated patients in the APEX study","volume":"108","author":"Chanan-Khan","year":"2006","journal-title":"Blood"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(74)90054-3","article-title":"Herpes simplex and herpes zoster in neoplasia","volume":"1","author":"Morison","year":"1974","journal-title":"Lancet"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.8","first-page":"1","article-title":"Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents","volume":"2","author":"Khalafallah","year":"2009","journal-title":"Medit J Hemat Infect Dis"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.9","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V74.4.1424.1424","article-title":"Herpes zoster infection after autologous bone marrow transplantation","volume":"74","author":"Schuchter","year":"1989","journal-title":"Blood J"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.10","first-page":"1121","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci1","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2118"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.12","first-page":"2","article-title":"Herpes zoster ophthalmicus: natural history, risk factors, clinical presentation, and morbidity","volume":"115","author":"Thomas","year":"2008","journal-title":"Ophthalmology"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00003226-199909000-00002","article-title":"Varicella-zoster virus eye disease","volume":"18","author":"Liesegang","year":"1999","journal-title":"Cornea"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0150.x"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.16","doi-asserted-by":"publisher","DOI":"10.1159\/000278713"},{"key":"2025082701361001000_2013.feb20_1.bcr2012007625.17","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-007-0007-y"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2012-007625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:36:21Z","timestamp":1756283781000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2012-007625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,20]]},"references-count":17,"alternative-id":["10.1136\/bcr-2012-007625"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2012-007625","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2013,2,20]]}}}